Core Viewpoint - MicroTech Medical-B (02235) expects its revenue for the year ending December 31, 2025, to be no less than RMB 650 million, representing a year-on-year growth of approximately 88.1% [1] - The company anticipates a net profit attributable to the parent company of no less than RMB 38 million for 2025, a significant increase of RMB 101.1 million compared to a net loss of RMB 63.1 million in 2024 [1] Revenue Growth - The company achieved substantial revenue growth during the reporting period, successfully turning a profit [1] - Key drivers of this growth include strong revenue from the continuous glucose monitoring system, significant international market expansion, and improved operational efficiency [1] Product and Market Expansion - The continuous glucose monitoring system, one of the company's core products, has seen robust revenue growth [1] - The LinX continuous glucose monitoring system has successfully entered multiple countries, leading to a notable increase in international revenue [1] Operational Efficiency - The company has implemented lean management practices, resulting in a significant improvement in operational efficiency [1] - The ratio of selling and administrative expenses to revenue has decreased substantially [1]
微泰医疗-B(02235)发盈喜 预计2025年度归母净利润不低于3800万元